Spots Global Cancer Trial Database for A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Official Title: A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Study ID: NCT04416451
Conditions
Study Description
Brief Summary: This study will help researchers understand how effective the combination of venetoclax and rituximab is in treating MZL in people who have not received a previous treatment for their cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope Cancer Center (Data collection only), Duarte, California, United States
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (All protocol Activities), Montvale, New Jersey, United States
Memorial Sloan Kettering Commack (All Protocol Activities), Commack, New York, United States
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Memorial Sloan Kettering Rockville Centre (All Protocol Activities), Rockville Centre, New York, United States
Contact Details
Name: Andrew Zelenetz, MD, PhD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
